PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort (NCT04477785)
The Parkinson's Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort
🩺 Plain-English Summary (8th-Grade Level)
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 30 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- Barrow Neurological Institute — Phoenix, Arizona
- Mayo Foundation for Medical Education and Research — Scottsdale, Arizona
- Banner Research Institute — Sun City, Arizona
- University of California San Diego — La Jolla, California
- Keck School of Medicine of USC — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- University of Colorado Anschutz Medical Campus — Aurora, Colorado
- Institute For Neurodegenerative Disorders — New Haven, Connecticut
- Parkinson's Disease& Movement Disorder Center of Boca Raton — Boca Raton, Florida
- University of Florida — Gainesville, Florida
- University of South Florida — Tampa, Florida
- Emory University School of Medicine — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- Johns Hopkins University — Baltimore, Maryland
- Boston University — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Cleveland Clinic Lou Ruvo Center for Brain Health — Las Vegas, Nevada
- Beth Israel Medical Center — New York, New York
- NYU Langone Health — New York, New York
- University of Rochester — Rochester, New York
- University of Cincinnati/Cincinnati Children's Hospital — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
📞 Contact the Study Coordinator
Phone: (877) 525-7764
Email: crainville@indd.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson Disease
- Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation — Tucson, Arizona
- Parkinson's Disease Progression Study — Aurora, Colorado
- To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Birmingham, Alabama
- Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) — Seattle, Washington
- Automated Imaging Differentiation of Parkinsonism — Birmingham, Alabama
- Study in Parkinson Disease of Exercise — Birmingham, Alabama
Explore by condition: All Parkinson Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.